PROFILE SOLUTIONS INC (OTCMKTS: PSIQ) had a 97.44% decrease in short interest. The SI of PSIQ was 100 shares in August, as published by FINRA. It has dropped 97.44% from the 3,900 previous shares. The stock increased 8.33% or $ 0.01 during the last trading session, reaching $ 0.13. About 1,600 shares traded. Profile Solutions, Inc. (OTCMKTS: PSIQ) has 0.00% as of August 7, 2018 and is. It has a 0.00% S & P500.
Analysts expect Osmotica Pharmaceuticals plc (NASDAQ: OSMT) to report $ -0.04 EPS on August 8. After having $ -0.12 EPS before, Osmotica Pharmaceuticals plc analysts see a growth of -66.67% EPS. The stock increased 2.25% or $ 0.07 during the last trading session, reaching $ 3.18. About 39,992 shares traded. Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has 0.00% since August 7, 2018 and is. It has a 0.00% S & P500.
The most notable recent news from Profile Solutions, Inc. (OTCMKTS: PSIQ) was published by: Globenewswire.com which launched: "PSIQ completes the end of the year 2018 audit Another TBT: PSIQ – GlobeNewswire" on July 17, 2019, also Seekingalpha.com with his article: "Profile Solutions to launch cannabis production in Israel – Seeking Alpha", published on March 27, 2019, Globenewswire.com Published: "PSIQ responds to the suspension of operations of the SEC Other OTC: PSIQ – GlobeNewswire" on June 21, 2019. More interesting news about Profile Solutions, Inc. (OTCMKTS: PSIQ) were published by: Globenewswire.com and his article: "PSIQ and Ecoland agree to extend another OTC: PSIQ – GlobeNewswire" published on July 1, 2019, as well as Globenewswire.comThe news article entitled: "PSIQ now expands CBD operations nationally and internationally in the midst of the successful approval of Farm Bill 2018 – GlobeNewswire" with publication date: December 21, 2018.
Profile Solutions, Inc. designs, develops, manufactures and sells security identification products and systems for Fortune 100 clients, law enforcement agencies and government agencies / facilities, and businesses related to the medical and recreational cannabis industry. The company has a market capitalization of $ 13.27 million. It offers Access-IT, an access control solution that is used to allow selected individuals access to closed offices of buildings and other safe areas; Profile W / R, a work release solution to track work release individuals from safe facilities; CannaVend, an OEM sales solution; Profile Tracker, an airline and transportation monitoring system for cargo, transportation, billing and reporting; and a biometric access control and time and attendance system. He currently has negative gains.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures and markets specialized products that target markets with underserved patient populations. The company has a market capitalization of $ 167.01 million. The approved products promoted by the company include specialized products in neurology, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy and postnatal periods. He currently has negative gains. Approved products not promoted by the Company include ER Methylphenidate for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium benzoate / sodium phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prenatal vitamins prescribed for nutritional requirements during pregnancy.
The most notable recent news from Osmotica Pharmaceuticals plc (NASDAQ: OSMT) was published by: Globenewswire.com which launched: "Osmotica Pharmaceuticals plc will provide the financial and commercial update for the second quarter of 2019 on August 8, 2019 – GlobeNewswire" on August 1, 2019, also Finance.Yahoo.com with his article: "Breakeven On The Horizon for Osmotica Pharmaceuticals plc (NASDAQ: OSMT) – Yahoo Finance", published on May 23, 2019, Globenewswire.com Published: “Osmotica Pharmaceuticals plc reports the financial results of the first quarter of 2019 and highlights the portfolio and commercial progress – GlobeNewswire” on May 9, 2019. More interesting news about Osmotica Pharmaceuticals plc (NASDAQ: OSMT) were published by: Nasdaq.com and his article: "Healthcare sector update for 03/28/2019: OSMT, AMRN, CTST – Nasdaq" published on March 28, 2019, as well as Globenewswire.comThe news article entitled: "Osmotica Pharmaceuticals plc reports the financial results of the fourth quarter and the full year 2018 and highlights the portfolio and commercial progress – GlobeNewswire" with publication date: March 27, 2019.
Receive news and ratings by email – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings with our FREE daily email newsletter.